Outlook Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
OTLK Nasdaq 2836 outlooktherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Outlook Therapeutics, Inc.

iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates - Aug 6th, 2026 8:35 pm
Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Aug 6th, 2026 8:00 am
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026 - Aug 6th, 2026 6:45 am
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards? - Aug 3rd, 2026 8:58 am
Twist Bioscience (TWST) Reports Q3 Loss, Beats Revenue Estimates - Aug 3rd, 2026 6:25 am
Outlook Therapeutics (OTLK) Is Down 24.3% After Landmark FDA Wet AMD Drug Approval - Has The Bull Case Changed? - Jul 29th, 2026 7:10 pm
Outlook Therapeutics (OTLK) Wins FDA Approval, Is The Valuation Already Priced In? - Jul 29th, 2026 3:08 pm
Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection - Jul 28th, 2026 3:31 pm
Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG - Jul 27th, 2026 11:45 am
Outlook Therapeutics wins FDA approval for Lytenava in wet AMD - Jul 27th, 2026 5:13 am
Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMD - Jul 27th, 2026 5:12 am
FDA scientists question Capricor data; Legend CEO steps down - Jul 27th, 2026 5:00 am
OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside - Jul 27th, 2026 12:47 am
FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions - Jul 24th, 2026 6:30 pm
OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab - Jul 24th, 2026 5:47 pm
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD - Jul 24th, 2026 12:40 pm
OTLK Stock Generates Buzz Ahead Of FDA Decision On Wet AMD Therapy – Retail Says Favorable Verdict Could Cause A ‘Big Boom’ - Jul 23rd, 2026 11:00 am
Outlook Therapeutics (OTLK) Gets July 29 PDUFA Date for LYTENAVA - Jul 14th, 2026 12:08 pm
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review - Jun 17th, 2026 8:20 am
Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In - Jun 16th, 2026 2:08 pm